New EORTC studies opened in 2011

EORTC trial 26091

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.

Target Accrual: 144 patients

Study Coordinator:

  • Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam

EORTC trial 58081

Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)

Target Accrual: 800 patients

Study Coordinator:

  • Helene Cave, Hôpital Robert Debre (AP-HP), Paris

EORTC trial 62091 – TRUSTS

A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma

Target Accrual: 370 patients

Study Coordinator:

  • Binh Bui-Nguyen – Institut Bergonie, Bordeaux

EORTC trial 08092 – MAPPING

Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy

Target Accrual:  587 patients

Study Coordinator:

  • Mary O’Brien – Royal Marsden Hospital, Sutton

EORTC trial 58LAE (Late Adverse Events)

Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998

Target Accrual: 3138 patients

Study Coordinator:

  • Caroline Piette – Centre Hospitalier Regional De La Citadelle, Liege

EORTC trial 26101

Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma

Target Accrual: 249 patients

Study Coordinator:

  • Wolfgang Wick – UniversitaetsKlinikum Heidelberg – Kopfklinik, Heidelberg

EORTC studies soon to be opened (in regulatory process)

EORTC trial 06083 – HOVON 100 ALL

Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial

Target Accrual:  – patients

Study Coordinator:

  • Jean-Pierre Marie – Hopital Saint Antoine AP-HP, Paris

EORTC trial 21082

Progression free survival (PFS) comparison between suberoylanilide hydroxamic acid (SAHA, Vorinostat TM) in combination with bortezomib (Velcade TM) and SAHA alone in refractory or recurrent advanced CTCL. A randomized study.

Target Accrual: 189 patients

Study Coordinator:

  • Pablo Luis Ortiz-Romero – Hospital Universitario, Madrid

EORTC trial 22055 – 08053

Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement – LUNG-ART

Target Accrual: 700 patients

Study Coordinator:

  • Cecile Le Pechoux – Institut Gustave Roussy, Villejuif

EORTC trial 40084-22084

A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma

Target Accrual: 950 patients

Study Coordinator:

  • Jean-Luc Van Laethem – Hospital Universitaire Erasme, Brussels

EORTC trial 55092

Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma

Target Accrual: 36 patients

Study Coordinator:

  • Ignace Vergote – U.Z. Gasthuisberg, Leuven

EORTC trial 62092-22092

A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS)

Target Accrual: 256 patients

Study Coordinator:

  • Sylvie Bonvalot – Institut Gustave Roussy, Villejuif

EORTC trial 65091 – 06093

Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups

Target Accrual: 556 patients

Study Coordinator:

  • Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen

EORTC trial 90101 – CREATE

Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET (“CREATE”)

Target Accrual: 582 patients

Study Coordinator:

  • Patrick Schoeffski – U.Z. Gasthuisberg, Leuven

 John Bean

Back to news list